Loading...
•
Jun 30
Edwards Lifesciences Q2 2025 Earnings Report
Edwards Lifesciences reported strong Q2 2025 results with double-digit revenue growth and raised guidance.
Key Takeaways
The company delivered $1.53B in revenue, driven by solid TAVR and TMTT growth, with EPS of $0.57 and adjusted EPS of $0.67. Net income reached $333M, and guidance for full-year sales and EPS was raised.
Revenue grew to $1.53B, up from $1.37B last year
TAVR sales reached $1.13B, driven by SAPIEN technology adoption
TMTT sales surged to $134.5M, fueled by PASCAL and EVOQUE
Full-year sales and EPS guidance raised due to strong performance
Edwards Lifesciences
Edwards Lifesciences
Edwards Lifesciences Revenue by Segment
Edwards Lifesciences Revenue by Geographic Location
Revenue by Segment
TAVR Revenue
CapyFin.comTMTT Revenue
CapyFin.comSurgical Revenue
CapyFin.comRevenue by Geographic Location
U.S. Revenue
CapyFin.comEurope Revenue
CapyFin.comJapan Revenue
CapyFin.comRest of World Revenue
CapyFin.com Forward Guidance
Edwards Lifesciences raised its full-year sales and EPS guidance, citing strong TAVR and TMTT performance.
Positive Outlook
- Full-year sales growth guidance raised to 9-10%
- TAVR sales guidance increased to $4.3B-$4.5B
- Adjusted EPS expected at high end of $2.40-$2.50
- Q3 sales projected between $1.46B-$1.54B
- Q3 adjusted EPS projected $0.54-$0.60
Challenges Ahead
- Gross profit margin declined year-over-year due to higher manufacturing costs
- Increased SG&A spending expected in second half
- Foreign exchange impacts on profitability
- Higher operating expenses anticipated due to JenaValve spending
- Impairment loss of $47.1M recorded in Q2
Revenue & Expenses
Visualization of income flow from segment revenue to net income